دورية أكاديمية
Molecular Profile of Intrahepatic Cholangiocarcinoma.
العنوان: | Molecular Profile of Intrahepatic Cholangiocarcinoma. |
---|---|
المؤلفون: | Andraus, Wellington, Tustumi, Francisco, de Meira Junior, José Donizeti, Pinheiro, Rafael Soares Nunes, Waisberg, Daniel Reis, Lopes, Liliana Ducatti, Arantes, Rubens Macedo, Rocha Santos, Vinicius, de Martino, Rodrigo Bronze, Carneiro D'Albuquerque, Luiz Augusto |
المصدر: | International Journal of Molecular Sciences; Jan2024, Vol. 25 Issue 1, p461, 18p |
مصطلحات موضوعية: | FIBROBLAST growth factor receptors, FIBROBLAST growth factor 2, CHOLANGIOCARCINOMA, IMMUNE checkpoint proteins, TUMOR proteins |
مستخلص: | Intrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This comprehensive characterization of ICC tumors sheds light on the disease's underlying biology and offers a foundation for more personalized treatment strategies. This is a narrative review of the prognostic and therapeutic role of the molecular profile of ICC. Knowing the molecular profile of tumors helps determine prognosis and support certain target therapies. The molecular panel in ICC helps to select patients for specific therapies, predict treatment responses, and monitor treatment responses. Precision medicine in ICC can promote improvement in prognosis and reduce unnecessary toxicity and might have a significant role in the management of ICC in the following years. The main mutations in ICC are in tumor protein p53 (TP53), Kirsten rat sarcoma virus (KRAS), isocitrate dehydrogenase 1 (IDH1), and AT-rich interactive domain-containing protein 1A (ARID1A). The rate of mutations varies significantly for each population. Targeting TP53 and KRAS is challenging due to the natural characteristics of these genes. Different stages of clinical studies have shown encouraging results with inhibitors of mutated IDH1 and target therapy for ARID1A downstream effectors. Fibroblast growth factor receptor 2 (FGFR2) fusions are an important target in patients with ICC. Immune checkpoint blockade can be applied to a small percentage of ICC patients. Molecular profiling in ICC represents a groundbreaking approach to understanding and managing this complex liver cancer. As our comprehension of ICC's molecular intricacies continues to expand, so does the potential for offering patients more precise and effective treatments. The integration of molecular profiling into clinical practice signifies the dawn of a new era in ICC care, emphasizing personalized medicine in the ongoing battle against this malignancy. [ABSTRACT FROM AUTHOR] |
Copyright of International Journal of Molecular Sciences is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
قاعدة البيانات: | Complementary Index |
كن أول من يترك تعليقا!